• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在未感染 SARS-CoV-2 的人群中,OC43 和 SARS-CoV-2 NP 之间存在交叉反应的细胞免疫,但不存在体液免疫:cT 细胞可能发挥作用。

Cross-reactive cellular, but not humoral, immunity is detected between OC43 and SARS-CoV-2 NPs in people not infected with SARS-CoV-2: Possible role of cT cells.

机构信息

Department of Immunology and Oncology, National Centre for Biotechnology, CNB-CSIC, Madrid, Spain.

Immunology Department, Hospital Universitario La Princesa IIS-IP, Madrid, Spain.

出版信息

J Leukoc Biol. 2022 Aug;112(2):339-346. doi: 10.1002/JLB.4COVCRA0721-356RRR. Epub 2022 Apr 5.

DOI:10.1002/JLB.4COVCRA0721-356RRR
PMID:35384035
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9088540/
Abstract

Multiple questions about SARS-CoV-2 humoral and cellular immunity remain unanswered. One key question is whether preexisting memory T or B cells, specific for related coronaviruses in SARS-CoV-2-unexposed individuals, can recognize and suppress COVID-19, but this issue remains unclear. Here, we demonstrate that antibody responses to SARS-CoV-2 antigens are restricted to serum samples from COVID-19 convalescent individuals. In contrast, cross-reactive T cell proliferation and IFN-γ production responses were detected in PBMCs of around 30% of donor samples collected prepandemic, although we found that these prepandemic T cell responses only elicited weak cT activation upon stimulation with either HCoV-OC43 or SARS-CoV-2 NP protein. Overall, these observations confirm that T cell cross-reactive with SARS-CoV-2 antigens are present in unexposed people, but suggest that the T cell response to HCoV-OC43 could be deficient in some important aspects, like T expansion, that might compromise the generation of cross-reactive T cells and antibodies. Understanding these differences in cellular responses may be of critical importance to advance in our knowledge of immunity against SARS-CoV-2.

摘要

关于 SARS-CoV-2 的体液和细胞免疫,仍有许多问题尚未得到解答。一个关键问题是,针对 SARS-CoV-2 未暴露个体中相关冠状病毒的预先存在的记忆 T 或 B 细胞,是否能够识别和抑制 COVID-19,但这个问题仍不清楚。在这里,我们证明了针对 SARS-CoV-2 抗原的抗体反应仅限于 COVID-19 恢复期个体的血清样本。相比之下,在大流行前采集的供体样本中约 30%的 PBMC 中检测到了交叉反应性 T 细胞增殖和 IFN-γ 产生反应,尽管我们发现这些大流行前 T 细胞反应仅在受到 HCoV-OC43 或 SARS-CoV-2 NP 蛋白刺激时才引发微弱的 cT 激活。总体而言,这些观察结果证实了未暴露人群中存在与 SARS-CoV-2 抗原交叉反应的 T 细胞,但表明针对 HCoV-OC43 的 T 细胞反应在某些重要方面可能存在缺陷,例如 T 细胞扩增,这可能会影响交叉反应性 T 细胞和抗体的产生。了解这些细胞反应的差异对于深入了解针对 SARS-CoV-2 的免疫可能至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/908c/9088540/61648374cfcc/JLB-112-339-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/908c/9088540/5e6ea1e2ea7b/JLB-112-339-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/908c/9088540/8ebf9e9e9d48/JLB-112-339-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/908c/9088540/165c6a19bc33/JLB-112-339-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/908c/9088540/61648374cfcc/JLB-112-339-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/908c/9088540/5e6ea1e2ea7b/JLB-112-339-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/908c/9088540/8ebf9e9e9d48/JLB-112-339-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/908c/9088540/165c6a19bc33/JLB-112-339-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/908c/9088540/61648374cfcc/JLB-112-339-g003.jpg

相似文献

1
Cross-reactive cellular, but not humoral, immunity is detected between OC43 and SARS-CoV-2 NPs in people not infected with SARS-CoV-2: Possible role of cT cells.在未感染 SARS-CoV-2 的人群中,OC43 和 SARS-CoV-2 NP 之间存在交叉反应的细胞免疫,但不存在体液免疫:cT 细胞可能发挥作用。
J Leukoc Biol. 2022 Aug;112(2):339-346. doi: 10.1002/JLB.4COVCRA0721-356RRR. Epub 2022 Apr 5.
2
Human Milk Antibodies Against S1 and S2 Subunits from SARS-CoV-2, HCoV-OC43, and HCoV-229E in Mothers with A Confirmed COVID-19 PCR, Viral SYMPTOMS, and Unexposed Mothers.母亲在确诊 COVID-19 PCR、出现病毒症状且未暴露于病毒的情况下,母乳中针对 SARS-CoV-2、HCoV-OC43 和 HCoV-229E 的 S1 和 S2 亚单位的人乳抗体。
Int J Mol Sci. 2021 Feb 9;22(4):1749. doi: 10.3390/ijms22041749.
3
The prospect of universal coronavirus immunity: characterization of reciprocal and non-reciprocal T cell responses against SARS-CoV2 and common human coronaviruses.普遍冠状病毒免疫的前景:针对 SARS-CoV2 和常见人类冠状病毒的相互和非相互 T 细胞反应的特征。
Front Immunol. 2023 Oct 13;14:1212203. doi: 10.3389/fimmu.2023.1212203. eCollection 2023.
4
Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination.既往抗 HCoV-OC43 免疫影响 SARS-CoV-2 疫苗接种后体液免疫的持久性和交叉反应性。
Front Cell Infect Microbiol. 2022 Sep 2;12:978440. doi: 10.3389/fcimb.2022.978440. eCollection 2022.
5
Functional SARS-CoV-2 cross-reactive CD4 T cells established in early childhood decline with age.在儿童早期建立的功能性 SARS-CoV-2 交叉反应性 CD4 T 细胞随年龄增长而下降。
Proc Natl Acad Sci U S A. 2023 Mar 21;120(12):e2220320120. doi: 10.1073/pnas.2220320120. Epub 2023 Mar 14.
6
Immunopeptidome profiling of human coronavirus OC43-infected cells identifies CD4 T cell epitopes specific to seasonal coronaviruses or cross-reactive with SARS-CoV-2.人冠状病毒OC43感染细胞的免疫肽组分析鉴定出季节性冠状病毒特有的或与SARS-CoV-2交叉反应的CD4 T细胞表位。
bioRxiv. 2022 Dec 1:2022.12.01.518643. doi: 10.1101/2022.12.01.518643.
7
Evidence for increased SARS-CoV-2 susceptibility and COVID-19 severity related to pre-existing immunity to seasonal coronaviruses.与季节性冠状病毒预先存在的免疫有关的 SARS-CoV-2 易感性增加和 COVID-19 严重程度的证据。
Cell Rep. 2021 Dec 28;37(13):110169. doi: 10.1016/j.celrep.2021.110169. Epub 2021 Dec 7.
8
Older adults lack SARS CoV-2 cross-reactive T lymphocytes directed to human coronaviruses OC43 and NL63.老年人缺乏针对人类冠状病毒 OC43 和 NL63 的 SARS-CoV-2 交叉反应性 T 淋巴细胞。
Sci Rep. 2020 Dec 8;10(1):21447. doi: 10.1038/s41598-020-78506-9.
9
HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients.补体缺陷患者中存在与 HCoV 和 SARS-CoV-2 发生交叉反应的 T 细胞。
Front Immunol. 2020 Dec 23;11:607918. doi: 10.3389/fimmu.2020.607918. eCollection 2020.
10
Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses.严重急性呼吸综合征冠状病毒 2 疫苗接种增强了对季节性人类冠状病毒的中和活性。
Clin Infect Dis. 2022 Aug 24;75(1):e653-e661. doi: 10.1093/cid/ciac057.

引用本文的文献

1
Human coronavirus OC43-elicited CD4 T cells protect against SARS-CoV-2 in HLA transgenic mice.人冠状病毒OC43诱导的CD4 T细胞在HLA转基因小鼠中对SARS-CoV-2具有保护作用。
Nat Commun. 2024 Jan 26;15(1):787. doi: 10.1038/s41467-024-45043-2.
2
Silent battles: immune responses in asymptomatic SARS-CoV-2 infection.无声的战斗:无症状 SARS-CoV-2 感染中的免疫反应。
Cell Mol Immunol. 2024 Feb;21(2):159-170. doi: 10.1038/s41423-024-01127-z. Epub 2024 Jan 15.
3
Evidence for broad cross-reactivity of the SARS-CoV-2 NSP12-directed CD4 T-cell response with pre-primed responses directed against common cold coronaviruses.

本文引用的文献

1
SARS-CoV-2 mRNA vaccination elicits a robust and persistent T follicular helper cell response in humans.SARS-CoV-2 mRNA 疫苗可在人体内引发强烈且持久的滤泡辅助性 T 细胞反应。
Cell. 2022 Feb 17;185(4):603-613.e15. doi: 10.1016/j.cell.2021.12.026. Epub 2021 Dec 23.
2
Single-reaction multi-antigen serological test for comprehensive evaluation of SARS-CoV-2 patients by flow cytometry.流式细胞术单次反应多重抗原血清学检测全面评估 SARS-CoV-2 患者。
Eur J Immunol. 2021 Nov;51(11):2633-2640. doi: 10.1002/eji.202149319. Epub 2021 Aug 19.
3
COVID-19 vaccine candidates based on modified vaccinia virus Ankara expressing the SARS-CoV-2 spike induce robust T- and B-cell immune responses and full efficacy in mice.
针对 SARS-CoV-2 NSP12 定向 CD4 T 细胞反应与针对普通感冒冠状病毒的预先存在反应的广泛交叉反应性的证据。
Front Immunol. 2023 May 5;14:1182504. doi: 10.3389/fimmu.2023.1182504. eCollection 2023.
4
Risk Factors of Severe COVID-19: A Review of Host, Viral and Environmental Factors.严重 COVID-19 的风险因素:宿主、病毒和环境因素的综述。
Viruses. 2023 Jan 7;15(1):175. doi: 10.3390/v15010175.
5
Association of cellular immunity with severity of COVID-19 from the perspective of antigen-specific memory T cell responses and cross-reactivity.从抗原特异性记忆T细胞反应和交叉反应性角度看细胞免疫与COVID-19严重程度的关联
Inflamm Regen. 2022 Nov 29;42(1):50. doi: 10.1186/s41232-022-00239-1.
6
High and Sustained Ex Vivo Frequency but Altered Phenotype of SARS-CoV-2-Specific CD4 T-Cells in an Anti-CD20-Treated Patient with Prolonged COVID-19.抗 CD20 治疗的 COVID-19 长期患者体内 SARS-CoV-2 特异性 CD4 T 细胞的体外高频率持续存在和表型改变。
Viruses. 2022 Jun 10;14(6):1265. doi: 10.3390/v14061265.
基于表达严重急性呼吸综合征冠状病毒2(SARS-CoV-2)刺突蛋白的改良安卡拉痘苗病毒的新型冠状病毒肺炎(COVID-19)候选疫苗可在小鼠体内诱导强烈的T细胞和B细胞免疫反应及完全效力。
J Virol. 2021 Mar 10;95(7). doi: 10.1128/JVI.02260-20. Epub 2021 Jan 7.
4
Low-Avidity CD4 T Cell Responses to SARS-CoV-2 in Unexposed Individuals and Humans with Severe COVID-19.未暴露个体和重症 COVID-19 患者对 SARS-CoV-2 的低亲和性 CD4 T 细胞反应。
Immunity. 2020 Dec 15;53(6):1258-1271.e5. doi: 10.1016/j.immuni.2020.11.016. Epub 2020 Nov 26.
5
Seroprevalence of SARS-CoV-2 in Hong Kong and in residents evacuated from Hubei province, China: a multicohort study.中国香港和从中国湖北省撤离居民的 SARS-CoV-2 血清阳性率:一项多队列研究。
Lancet Microbe. 2020 Jul;1(3):e111-e118. doi: 10.1016/S2666-5247(20)30053-7. Epub 2020 Jun 3.
6
Characterization of pre-existing and induced SARS-CoV-2-specific CD8 T cells.鉴定存在的和诱导的 SARS-CoV-2 特异性 CD8 T 细胞。
Nat Med. 2021 Jan;27(1):78-85. doi: 10.1038/s41591-020-01143-2. Epub 2020 Nov 12.
7
Potential Cross-Reactive Immunity to SARS-CoV-2 From Common Human Pathogens and Vaccines.常见人类病原体和疫苗对 SARS-CoV-2 的潜在交叉反应性免疫。
Front Immunol. 2020 Oct 16;11:586984. doi: 10.3389/fimmu.2020.586984. eCollection 2020.
8
Preexisting and de novo humoral immunity to SARS-CoV-2 in humans.人类对 SARS-CoV-2 的预先存在和新产生的体液免疫。
Science. 2020 Dec 11;370(6522):1339-1343. doi: 10.1126/science.abe1107. Epub 2020 Nov 6.
9
SARS-CoV-2 Cysteine-like Protease Antibodies Can Be Detected in Serum and Saliva of COVID-19-Seropositive Individuals.SARS-CoV-2 半胱氨酸蛋白酶抗体可在 COVID-19 血清阳性个体的血清和唾液中检测到。
J Immunol. 2020 Dec 1;205(11):3130-3140. doi: 10.4049/jimmunol.2000842. Epub 2020 Nov 4.
10
Prior presumed coronavirus infection reduces COVID-19 risk: A cohort study.既往疑似冠状病毒感染降低 COVID-19 风险:一项队列研究。
J Infect. 2020 Dec;81(6):923-930. doi: 10.1016/j.jinf.2020.10.023. Epub 2020 Oct 27.